Full Text View
Tabular View
No Study Results Posted
Related Studies
Arterial Disease Multifactorial Intervention Trial (ADMIT)
This study has been completed.
First Received: October 27, 1999   Last Updated: January 10, 2006   History of Changes
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT00000539
  Purpose

To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.


Condition Intervention Phase
Arterial Occlusive Diseases
Cardiovascular Diseases
Heart Diseases
Vascular Diseases
Diabetes Mellitus
Drug: niacin
Drug: pravastatin
Drug: beta-carotene
Drug: vitamin E
Behavioral: dietary supplements
Drug: vitamin C
Drug: warfarin
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: September 1992
Estimated Study Completion Date: March 1999
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Men and women with symptomatic or asymptomatic peripheral arterial disease.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000539

Sponsors and Collaborators
Investigators
Investigator: Kathryn Davis Statistics and Epidemiology Research Corporation
  More Information

Publications:
Study ID Numbers: 82
Study First Received: October 27, 1999
Last Updated: January 10, 2006
ClinicalTrials.gov Identifier: NCT00000539     History of Changes
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Antimetabolites
Beta Carotene
Antioxidants
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Pravastatin
Vitamins
Therapeutic Uses
Cardiovascular Diseases
Micronutrients
Arterial Occlusive Diseases
Metabolic Diseases
Heart Diseases
Growth Substances
Antilipemic Agents
Vascular Diseases
Diabetes Mellitus
Endocrine System Diseases
Enzyme Inhibitors
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Protective Agents
Pharmacologic Actions
Vitamin E
Glucose Metabolism Disorders
Ascorbic Acid

ClinicalTrials.gov processed this record on November 09, 2009